Business Award - March 29, 2021
Peter Rothschild – SEB’s Best International Growth
Peter Rothschild, founder and chairman of BioGaia, received SEB’s award “Best International Growth” in the final of the EY Entrepreneur Of The Year. The motivation for “Best International Growth”: “Peter Rothschild has built a company that today is a world leader within its niche. Through a network of distributors the company’s products reaches more than […]
Biotech Business - June 30, 2014
BioGaia expands with new production facility
BioGaia’s subsidiary TwoPac is setting up another production unit in Eslöv, in the south of Sweden. TwoPac AB was founded in 2002 to develop and manufacture packaging solutions for probiotics and is since June 2013 entirely owned by BioGaia. TwoPac mainly produces drops and straws with probiotics. During 2012 a new factory was built in […]
Agreement - June 18, 2014
BioGaia enters new agreements
The Swedish health care company has signed a distribution agreement for India and an exclusive agreement in the UK. BioGaia has signed a non-exclusive agreement with Pharma Base SA for the rights to sell BioGaia’s ProTectis Baby Drops in India. Under the agreement, Pharma Base will cooperate with a local distributor for the marketing and […]
Uncategorized - January 16, 2014
BioGaia study published in JAMA Pediatrics
The study shows that it’s possible to prevent colic in healthy infants. A study of 468 healthy newborns shows that infants given the probiotic Lactobacillus reuteri Protectis cried less than half as long as infants given a placebo. The infants given Lactobacillus reuteri Protectis also had significantly fewer daily regurgitations and were less constipated compared […]
Agreement - November 21, 2013
Biogaia signs exclusive agreement in Brazil
Biogaia has signed a long-term agreement with Aché for the exclusive rights to sell Biogaia’s probiotic drops and tablets in Brazil. According to Biogaia the products will be co-branded with expected launch in mid-2014. ”We are pleased to engage in an enduring collaboration with BioGaia, enabling the launch of relevant products in the Brazilian market. […]
Biotech Business - November 12, 2013
BioGaia plans to invest in project aimed at developing drug for NEC
The board of BioGaia has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly fatal disease Necrotising Enterocolitis (NEC), which affects premature infants. BioGaia will invest SEK 42 million in the project over a two-year period. The […]
